Interferons in the treatment of multiple myeloma.

Bergsagel, Daniel E.; Wussow, Peter von; Alexanian, R.; Avvisati, Giuseppe; Bataille, Régis; Barlogie, Bart; Ec, Borden; Caligaris-Cappio, Federico; Deicher, H.; Durie, B G; Giles, Francis J.; Huhn, D.; Klein, Bernard; Kyle, RA; Ludwig, Hans; Mellstedt, H; Peest, D.; Salmon, SE; Westin, Jan

doi:10.1200/jco.1990.8.8.1444

Cited by 5 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interferon as a single agent has been shown to produce responses when used to treat newly diagnosed active multiple myeloma ( Mellstedt et al , 1979 ; Bergsagel et al , 1990 ). The way by which α‐IFN affects the disease process of multiple myeloma in vivo is poorly understood.…”

Section: Discussionmentioning

confidence: 99%

MRC trial of α2b‐interferon maintenance therapy in first plateau phase of multiple myeloma

Drayson¹,

Chapman²,

Dunn

et al. 1998

Br J Haematol

View full text Add to dashboard Cite

Plateau phase has been achieved in 64% of all newly diagnosed patients with multiple myeloma treated with the ABCM (adriamycin, BiCNU, cyclophosphamide and melphalan) regimen in the Medical Research Council (MRC) trials; this stable clinical stage of the disease is associated with no more than minimal symptoms. Several studies have found that α‐interferon (α‐IFN) maintenance therapy increases the duration of plateau phase, but it is less clear if this translates into prolonged survival. We report the effect of α‐IFN on the duration of plateau phase and overall survival in a trial with 284 patients who were randomized to receive α2b‐IFN (Intron‐A) or no maintenance therapy during first plateau phase. The minimum follow‐up after randomization was 21 months. There was no significant difference in the overall survival between the two treatment groups (χ2 = 0.32, P = 0.57). There was a trend towards longer relapse‐free survival in the patients allocated α‐IFN, but this trend to longer plateau phase was not statistically significant (χ2 = 1.62, P = 0.2). Disease progression at relapse on α‐IFN appears to be more severe with greater elevations from plateau levels of serum paraprotein (P = 0.06) and β2‐microglobulin (P = 0.03) levels. Physicians tended to start chemotherapy sooner after diagnosis of relapse when patients had received α‐IFN (P = 0.16). Although, in common with most other studies, there is a trend for patients treated with α‐IFN to have a longer plateau phase, this is counteracted by morbidity attributable to the treatment and a somewhat shortened survival post relapse. Meta‐analysis of interferon trials is required to assess whether the minor trend for longer survival in patients maintained on α‐IFN found in some studies is significant and, if so, the extent of this advantage.

show abstract

Section: Discussionmentioning

confidence: 99%

MRC trial of α2b‐interferon maintenance therapy in first plateau phase of multiple myeloma

Drayson¹,

Chapman²,

Dunn

et al. 1998

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…Our data do not confirm these results so far, which might be explained by different chemo therapy induction schemes used in both studies. This and other controlled trials testing Ifn-a for maintenance treatment are currently in progress [5] to settle this important question.…”

Section: Discussionmentioning

confidence: 99%

“…Therefore, we have initiated a prospective multicenter trial to test VBAMDex versus Melphalan intravenously and prednisone (MivP) for remission induction in stage III mye loma patients. Intcrferon-a (Ifn-a) producing a response rate of 20% when administered as a single agent [5] has recently been propagated to be beneficial for maintenance of chemo therapy induced remission [6]. This observation is subject to review in our current study.…”

Section: Introductionmentioning

confidence: 94%

Melphalan and Prednisone (MP) versus Vincristine, BCNU, Adriamycin, Melphalan and Dexamethasone (VBAM Dex) Induction Chemotherapy and Interferon Maintenance Treatment in Multiple Myeloma

Peest¹,

Deicher²,

Coldewey³

et al. 1990

Oncol Res Treat

View full text Add to dashboard Cite

277 untreated multiple myeloma patients of stage I (n = 33), II (n = 106) and III (n = 138) entered the study. Patients of stage II presenting a progressive tumor (n = 64) initially or during observation (n = 14) were treated with MivP (remissions: 61%). 138 patients of stage III were randomized to receive MivP or VBAMDex treatment. 51% of MivP treated patients responded versus 70% of the VBAMDex group. 71 responders of stage II and III with stable disease were randomized on Ifn-Α maintenance versus no maintenance treatment. The relapse rate in both groups was 50% after 7 months. 75% survival was > 36 months in stage II and 11 months in stage III patients.

show abstract

A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group

Peest¹,

Deicher²,

Coldewey³

et al. 1995

European Journal of Cancer

View full text Add to dashboard Cite

Interferons in the treatment of multiple myeloma.

Cited by 5 publications

References 0 publications

MRC trial of α2b‐interferon maintenance therapy in first plateau phase of multiple myeloma

MRC trial of α2b‐interferon maintenance therapy in first plateau phase of multiple myeloma

Melphalan and Prednisone (MP) versus Vincristine, BCNU, Adriamycin, Melphalan and Dexamethasone (VBAM Dex) Induction Chemotherapy and Interferon Maintenance Treatment in Multiple Myeloma

A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group

Contact Info

Product

Resources

About